J&J beats on earnings but warns of potential job cuts

  • 📰 RTEbusiness
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 61%

Business News News

Johnson & Johnson has posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar.

J&J Chief Financial Officer Joseph Wolk said the U.S. healthcare conglomerate is looking at"right sizing" itself, particularly as it moves from being a three-segment business to a two segment business through the spinoff of its consumer unit.

J&J said it was not immune to the affects of inflation on its business and the impact of a strong dollar, despite"healthcare being more resilient" than most industries. "We are looking at making sure that our resources are deployed on those projects, those initiatives, those services that really add the most value for our business," Wolk told Reuters.

The share move was mainly due to macroeconomic and currency concerns which are not unique to J&J, said Edward Jones analyst John Boylan.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 16. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

European stocks are cheap, but risks remainPrice/earnings ratios will look less attractive when earnings inevitably fall
Source: IrishTimes - 🏆 3. / 98 Read more »